A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 427-443

  Citrome, Leslie ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Aripiprazole; Bipolar disorder; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; BROMOCRIPTINE; CARBAMAZEPINE; CHOLESTEROL; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; GLUCOSE; HALOPERIDOL; HALOPERIDOL DECANOATE; HEMOGLOBIN; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; TRIACYLGLYCEROL; VALPROIC ACID;

AGITATION; AKATHISIA; ANXIETY; BINDING AFFINITY; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INDIVIDUALIZATION; INSOMNIA; LONG TERM CARE; META ANALYSIS; METABOLIC DISORDER; MIXED MANIA AND DEPRESSION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PARANOIA; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; VAGINITIS; VOMITING; WEIGHT GAIN;

EID: 33847249979     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.427     Document Type: Review

References (66)

1. Barnas ME, Hussain N, Petrides G. 2005. Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry, 66:1339.
2. Bhati MT. 2005. What makes aripiprazole the different antipsychotic. Current Psychiatry, 4:51-60.
3. Bristol-Myers Squibb. 2001. CN138-001: A multicenter, randomized, double-blind, placebo controlled study of three fixed doses of aripiprazole in the treatment of patients with acute schizophrenia [online]. Dated 27 July 2001. Accessed 16 January 2006. URL: http://ctr.bms.com/pdf/CN138001.pdf
4. Bristol-Myers Squibb. 2003a. CN138-010: A multicenter, randomized, double-blind, placebo controlled study of aripiprazole in the maintenance treatment of patients with bipolar disorder [online]. Dated 17 December 2003. Accessed 19 January 2006. URL: http://ctr.bms.com/pdf/ CN138010.pdf.
5. Bristol-Myers Squibb. 2003b. Supplemental new drug application submitted for ABILIFY(TM) (aripiprazole) for the treatment of acute bipolar mania [online]. Press release 16 July 2003. Accessed 19 January 2006. URL: http://www.prnewswire.com.
6. Bristol-Myers Squibb. 2004a. CN138-002 (26-52 week): A multicenter, randomized, double-blind safety and tolerability study of flexible doses of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia [online]. Dated 1 December 2004. Accessed 17 January 2006. URL: http://ctr.bms.com/pdf/CN138002.pdf.
7. Bristol-Myers Squibb. 2004b. CN138-032: A multicenter, randomized, double-blind study of flexible doses of aripiprazole vs perphenazine in the treatment of patients with treatment-resistant schizophrenia [online]. Dated 14 January 2004. Accessed 17 January 2006. URL: http://ctr.bms.com/pdf/CN138032.pdf.
8. Bristol-Myers Squibb. 2004c. CN138-047: A multicenter, randomized, double-blind, placebo controlled, 26 week study of a fixed dose of aripiprazole in the treatment of stabilized patients with chronic schizophrenia: open-label randomized, 52 week extension phase [online]. Dated 25 May 2004. Accessed 16 January 2006. URL: http://ctr.bms.com/pdf/ CN138047.pdf.
9. Bristol-Myers Squibb. 2004d. CN138-087: A prospective, multicenter, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practices [online]. Dated 29 April 2004. Accessed 17 January 2006. URL: http://ctr.bms.com/pdf/CN138087.pdf.
10. Bristol-Myers Squibb. 2005. CN138-003: A multicenter, double-blind, randomized comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia [online]. Dated 21 January 2005. Accessed 16 January 2006. U'RL: http://ctr.bms.com/pdf/ CN138003.pdf.
11. Bristol-Myers Squibb. 2006. Abilify (aripiprazole tablets and oral solution). In Physician's Desk Reference. 60th ed. Montvale, NJ: Thomson PDR. p 916-22.
12. Burris KD, Molski TF, Xu C, et al. 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther, 302:3 81-9.
13. Chakos M, Lieberman JA, Hoffman E, et al. 2001. Effectiveness of second-generation antipsychotics in patients with treatment resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry, 158:518-26.
14. Chakraborty N, Johnston T. 2004. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol, 19:351-3.
15. Citrome L, Bilder RM, Volavka J. 2002. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract, 8:205-15.
16. Citrome L, Goldberg JF, Stahl SM. 2005a. Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry, 13:28-42.
17. Citrome L, Jaffe A, Levine J, et al. 2005b. Dosing of quetiapine in schizophrenia - how clinical practice differs from registration studies. J Clin Psychiatry, 66:1512-6.
18. Citrome L, Jaffe A, Levine J. 2005c. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol, 25:388-91.
19. Citrome L, Josiassen R, Bark N, et al. 2005d. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol, 45:89-93.
20. Citrome L, Volavka J. 2002. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry, 10:280-91.
21. Clarke LA, Lindenmayer JP, Kaushik S. 2006. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry, 67:674-5.
22. De Deyn P, Jeste DV, Swanink R, et al. 2005. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol, 25:463-7.
23. DeQuardo JR, Tandon R. 1998. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J Psychiatr Res, 32:229-42.
24. DeQuardo JR. 2004. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? J Clin Psychiatry, 65:132-3.
25. Dew RE, Rosenquist PB, McCall WV. 2005. Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignat syndrome. Int J Adolesc Med Health, 17:185-6.
26. Duggal HS. 2004. Aripiprazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry, 49:151.
27. Duggal HS, Kithas J. 2005. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry, 162:397-8.
28. Duggal HS, Mendhekar DN. 2006. High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry, 67:675-6.
29. El-Sayeh HG, Morganti C. 2004. Aripiprazole for schizophrenia. Cochrane Database Syst Rev, (2):CD004578.
30. Fleischhacker WW. 2005. Aripiprazole. Expert Opin Pharmacother, 6:2091-101.
31. Glick ID, Duggal V, Hodulik. 2006. Aripiprazole as a dopamine partial agonist. J Clin Psychopharmacol, 26:101-3.
32. Harrison TS, Perry CM. 2004. Aripiprazole - A review of its use in schizophrenia and schizoaffective disorder. Drugs, 64:1715-36.
33. Henderson DC, Kunkel L, Nguyen DD, et al. 2006. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand, 113:142-7.
34. Jagadheesan K, Muirhead D. Aripiprazole for acute bipolar mania. Am J Psychiatry, 161:1926-7.
35. Kane J, Carson W, Kujawa M, et al. 2003. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. 156th Annual Meeting of the American Psychiatric Association. 2003 May 17-22; San Francisco, CA, USA. Poster presentation NR537.
36. Kane JM, Carson WH, Saha AR, et al. 2002. Efficacy and safety of aripiprazole and haloperidol vs placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry, 63:763-71.
37. Kasper S, Lerman MN, McQuade RD, et al. 2003. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol, 6:325-37.
38. Keck PE, Calabrese JR, McQuade RD, et al. 2006. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry, 67:626-37.
39. Keck PE Jr., Marcus R, Tourkodimitris S, et al. 2003. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry, 160:1651-8.
40. Kraemer HC, Kupfer DJ. 2005. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry, doi:10.1016/j.biopsych.2005.09.014.
41. Lee BH, Kim YK, Park SH. 2006. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry, doi:10.1016/ j.pnpbp.2006.02.001
42. Lieberman JA, Stroup TS, McEvoy JP et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353:1209-23.
43. Lim S, Pralea C, Schnitt J, et al. 2004. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry, 65:1284-5.
44. Lyseng-Williamson KA, Perry CM. 2004. Aripiprazole in acute mania associated with bipolar I disorder. CNS Drugs, 18:367-76.
45. Marder SR, McQuade RD, Stock E, et al. 2003. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res, 61:123-36.
46. McGavin J, Goa KL. 2002. Aripiprazole. CNS Drugs, 16:779-86.
47. McQuade R, Stock E, Marcus R, et al. 2004. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry, 65(Suppl 18):47-56.
48. Mendhekar DN, Andrade C. 2005. Galactorrhea with aripiprazole. Can J Psychiatry, 50:243.
49. Pigott TA, Carson WH, Saba AR, et al. 2003. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry, 64:1048-56.
50. Potkin SG, Saha AR, Kujawa MJ, et al. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, 60:681-90.
51. Prescrire Editorial Staff. 2005. Aripiprazole: new drug. Just another neuroleptic. Prescrire Int, 14:163-7.
52. Ramaswamy S, Vijay D, William M, et al. 2004. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol, 19:45-8.
53. Reeves RR, Mack JE. 2004. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry, 161:1308.
54. Ruffatti A, Minervini L, Romano M, et al. 2005. Galactorrhea with aripiprazole. Psychother Psychosom, 74:391-2.
55. Sachs G, Sanchez R, Marcus R, et al. 2006. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo controlled study. J Psychopharmacol, doi:10.1177/ 0269881106059693.
56. Saba AR, Ali MW, Ingenito GG, et al. 2002. Safety and tolerability of aripiprazole at doses higher than 30 mg [abstract]. Int J Neuropsychopharmacol, 5(Suppl 1):S185.
57. Shapiro DA, Renock S, Arrington E, et al. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28:1400-11.
58. Shayegan DK, Stahl SM. 2004. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr, 9(Suppl 11):6-14.
59. Spalding S, Alessi NE, Radwan K. 2004. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry, 43:1457-8.
60. Stahl SM. 2002. Essential psychopharmacology of antipsychotics and mood stabilizers. New York: Cambridge University Press.
61. Srephichit S, Sanchez R, Bourgeois JA. 2006. Neuroleptic Malignant Syndrome and Aripiprazole in an Antipsychotic-naive Patient. J Clin Psychopharmacol, 26:94-5.
62. Tandon R, Marcus RN, Stock EG, et al. 2006. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res. In press; corrected proof doi:10.1016/j.physletb.2003.10.071.
63. Travis MJ, Burns T, Dursun S, et al. 2005. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract, 59:485-95.
64. Wahlbeck K, Cheine M, Essali A, et al. 1999. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry, 156:990-9.
65. Vieta E, Bourin M, Sanchez R, et al. 2005. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry, 187:235-42.
66. Ziegenbein M, Sieberer M, Calliess IT, et al. 2005. Combination of clozapine and aripiprazolc: a promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry, 39:840-1.